omniture
信达生物制药(苏州)有限公司 Innovent BiologicsInc

Latest News

Sintilimab in Combination with Chemotherapy Meets Overall Survival Primary Endpoint in the Global Phase 3 ORIENT-15 Study for the First-Line Treatment of Esophageal Squamous Cell Carcinoma

SAN FRANCISCO and SUZHOU, China, June 23, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-06-23 09:16 1309

Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology

SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-06-21 08:00 1825

Innovent Announces First Patient Dosed in the Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion

SAN FRANCISCO and SUZHOU, China, June 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-06-18 08:00 1280

Innovent Announces First Overweight or Obese Subject Dosed in A Phase 2 Clinical Trial of IBI362 (a GLP-1 and Glucagon Receptor Dual Agonist) in China

SAN FRANCISCO and SUZHOU, China, June 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-06-15 12:00 2188

Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",...

2021-06-07 08:00 5502

Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",...

2021-06-07 08:00 5759

Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",...

2021-06-07 08:00 5706

Clinical Trial Results of the BCMA CAR-T Co-developed by Innovent and IASO Biotherapeutics Commented in American Society of Hematology's Medical Journal "Blood"

SAN FRANCISCO, U.S. and SUZHOU, China, June 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno...

2021-06-03 08:00 3068

Innovent Biologics and AnHeart Therapeutics Jointly Announce Exclusive License Agreement for Taletrectinib in Greater China

SAN FRANCISCO and SUZHOU, China, June 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (...

2021-06-01 08:00 2465

Innovent Announces First Patient Dosed in China in the Global Phase 3 Clinical Trial of Pemigatinib as the First-line Treatment of Unresectable or Metastatic Cholangiocarcinoma

SAN FRANCISCO and SUZHOU, China, May 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2021-05-25 08:00 9665

Innovent Will Publish Multiple Clinical Data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN FRANCISCO and SUZHOU, China, May 17, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2021-05-17 09:00 2220

Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, April 13, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2021-04-13 08:00 2374

Innovent Announces Parsaclisib (IBI376) was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Follicular Lymphoma

SAN FRANCISCO and SUZHOU, China, March 31, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2021-03-31 08:00 2298

Innovent Announced Financial Results for Full Year Ended December 31, 2020 and Corporate Progress

SAN FRANCISCO and SUZHOU, China, March 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2021-03-30 20:52 1882
12345 ... 7